Abionyx Completes CER-001 Bioproduction Chain Setup With AXPLORA
Abionyx Pharma has finalized the production chain for CER-001 with AXPLORA, with purification set for its Pompey site in France, according to Reuters.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Abionyx Pharma SA said it has finalized the structuring of the CER-001 bioproduction chain through a strategic partnership with AXPLORA. The company describes this as a major milestone toward a possible commercialization of the drug.
Purification for CER-001 will be carried out at AXPLORA's site in Pompey, France. The two parties have also completed an end-to-end manufacturing process for recombinant human apoA-I.
Meanwhile, Abionyx continues its regulatory steps for LCAT deficiency and is preparing a Phase 2b sepsis trial.
why it matters
For markets this is news at the level of a small biotech company: it has no direct effect on commodities, currencies or indices. Investor interest depends on the progress of regulatory procedures and clinical trials rather than on manufacturing logistics.
tags
instruments
sources
- Abionyx Finalizes Structuring Of CER-001 Bioproduction Chain Through Partnership With AXPLORA — Reuters, 27 October 2026 at 07:27 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗